Pilocarpine hydrochloride 0.4% · ophthalmic solution
Aesthetics/Presbyopia
Approved uses
Presbyopia in adults
One drop in each eye, repeatable once after 2 to 3 hours for an effect lasting up to 8 hours; daily or as needed, up to twice each day
A low-concentration, preservative-free pilocarpine: the 0.4% strength is chosen to limit brow ache and dim vision
Contraindications
Known hypersensitivity to the active ingredient or to any of the excipients
Pilocarpine hydrochloride 0.4% (4 mg/mL), 0.4 mL single-patient-use vials, 10, 20, 30, or 60 vials per box
Pilocarpine hydrochloride is a cholinergic muscarinic agonist which activates muscarinic receptors located at smooth muscles such as the iris sphincter muscle and ciliary muscle. QLOSI contracts the iris sphincter muscle, constricting the pupil to enhance the depth of focus and improve near visual acuity while maintaining some pupillary response to light.
Warnings & Precautions
- Blurred vision: Miotics, including QLOSI, may cause accommodative spasm. Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Patients may also experience temporary dim or dark vision, so advise caution in night driving and other hazardous activities in poor illumination.
- Risk of retinal detachment: Rare cases of retinal detachment have been reported with miotics when used in susceptible individuals and those with pre-existing retinal disease. Examination of the retina is advised in all patients before initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.
- Iritis: QLOSI is not recommended to be used when iritis is present because adhesions (synechiae) may form between the iris and the lens.
- Contact lens wear: Advise wearers to remove their lenses before instillation and to wait 10 minutes after dosing before reinserting them.
- Potential for eye injury or contamination: To prevent eye injury or contamination, avoid touching the tip of the single-patient-use vial to the eye or to any other surface.
Common Side Effects
The most commonly reported treatment-related adverse events, in 5% to 8% of patients, were instillation site pain and headache. Blurred vision was reported in 2% to 5% of patients. The majority of the adverse events were mild, transient and self-resolving.
Pregnancy: No adequate and well-controlled studies in pregnant women; oral pilocarpine given to pregnant rats throughout organogenesis and lactation did not produce adverse effects at clinically relevant doses.
Lactation: No data on the presence of pilocarpine in human milk, the effects on breastfed infants, or the effects on milk production; pilocarpine and/or its metabolites are excreted in the milk of lactating rats following single oral administration; systemic levels of pilocarpine following topical ocular administration are low, and it is not known whether measurable levels would be present in maternal milk following ocular administration of QLOSI; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for QLOSI and any potential adverse effects on the breastfed child.
Presbyopia is an age-related condition that does not appear in the pediatric population.